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Abstract 
Background: Phosphodiesterases (PDE) are a superfamily of enzymes that hydrolyse cyclic nucleotides (cAMP/
cGMP), signal molecules in transduction pathways regulating crucial aspects of cell life. PDEs regulate the intensity 
and duration of the cyclic nucleotides signal modulating the downstream biological effect. Due to this critical role 
associated with the extensive distribution and multiplicity of isozymes, the 11 mammalian families (PDE1 to PDE11) 
constitute key therapeutic targets. PDE5, one of these cGMP-specific hydrolysing families, is the molecular target of 
several well known drugs used to treat erectile dysfunction and pulmonary hypertension. Kluyveromyces lactis, one of 
the few yeasts capable of utilizing lactose, is an attractive host alternative to Saccharomyces cerevisiae for heterologous 
protein production. Here we established K. lactis as a powerful host for the quantitative production of the murine 
PDE5 isoforms.
Results: Using the promoter of the highly expressed KlADH3 gene, multicopy plasmids were engineered to produce 
the native and recombinant Mus musculus PDE5 in K. lactis. Yeast cells produced large amounts of the purified A1, A2 
and A3 isoforms displaying  Km,  Vmax and Sildenafil inhibition values similar to those of the native murine enzymes. 
PDE5 whose yield was nearly 1 mg/g wet weight biomass for all three isozymes (30 mg/L culture), is well tolerated by 
K. lactis cells without major growth deficiencies and interferences with the endogenous cAMP/cGMP signal transduc-
tion pathways.
Conclusions: To our knowledge, this is the first time that the entire PDE5 isozymes family containing both regula-
tory and catalytic domains has been produced at high levels in a heterologous eukaryotic organism. K. lactis has been 
shown to be a very promising host platform for large scale production of mammalian PDEs for biochemical and struc-
tural studies and for the development of new specific PDE inhibitors for therapeutic applications in many pathologies.
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Background
Cyclic nucleotides (cNMP) are the components of evo-
lutionary conserved transduction pathways controlling 
all aspects of cell life [1] and phosphodiesterases (PDEs) 
have a central role in the cAMP/cGMP hydrolysis [2, 3]. 
These enzymes modulate the amplitude and duration of 
the cAMP/cGMP signal within the cell and ultimately the 
localization, the composition and the activity of protein 
kinase A (PKA) and G. To date eleven families of class I 
PDE isozymes, encoded by 24 distinct genes, have been 
identified in higher eukaryotes displaying distinct bio-
chemical properties and substrate specificity [4]. PDE5, 
one of these families containing three isoforms encoded 
by Pde5a1, Pde5a2 and Pde5a3, has a major role as 
cGMP-dependent regulator of vascular smooth muscle 
contraction. This activity is the molecular target of sev-
eral well-known drugs used to treat erectile dysfunction 
and pulmonary hypertension [5].
In Saccharomyces cerevisiae two genes for PDE 
enzymes that hydrolyse cAMP are present and glucose 
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is the extracellular signal that triggers their expression 
as well as the cAMP-dependent activation of PKA [6, 7]. 
Pde1 is a “class II” hydrolysing enzyme with low affin-
ity for cAMP and cGMP [8, 9]. Pde2 has high affinity for 
cAMP and belongs to class I of the higher eukaryotes 
superfamily [10]. These two pde mutants, together with 
fission yeast mutants strains have been successfully used 
as powerful genetic tools for the expression and clon-
ing of mammalian PDE genes. The activities have been 
biochemically characterized and brilliant yeast genetic 
selections were developed for the identification of many 
specific PDE inhibitors [11–14]. However, to our knowl-
edge, no yeast has been engineered for the quantitative 
production of mammalian PDEs.
Kluyveromyces lactis harbours two uncharacterized 
PDE genes closely related to those of S. cerevisiae sug-
gesting their involvement in the regulation of common 
pathways. K. lactis is a Crabtree–negative GRAS (Gener-
ally Recognized as Safe) yeast in which both respiratory 
and fermentative metabolisms coexist during its growth 
on glucose [15]. Extensive metabolic and physiological 
studies have established K. lactis as the fermentative-defi-
cient model equivalent but alternative to the respiratory-
deficient S. cerevisiae petite mutants [16–23]. Indeed, K. 
lactis has been shown to be an attractive host for heter-
ologous protein production [24], for genetic studies and 
industrial applications, being one of the few yeast spe-
cies capable of growing on lactose as a sole carbon source 
[25–27].
The choice of the promoter is an important element in 
having an efficient and regulated expression of the gene 
of interest [24, 28]. In these reviews the authors listed the 
constitutive/regulated yeast promoters successfully used 
for the production of recombinant proteins. In this paper, 
the well-characterized promoter of KlADH3, a gene 
highly induced by all respiratory carbon sources with the 
exception of ethanol that specifically mediates its repres-
sion [29–32], was used for the construction of pKD1-
derived expression vectors. pKD1 is a natural plasmid 
originally isolated from Kluyveromyces drosophilarum, 
but stably maintained in K. lactis [33–35]. The use of the 
KlADH3 promoter and K. lactis for the production of 
PDE5A isoforms under respiratory growth conditions, 
has been preferred to the Crabtree–positive S. cerevisiae 
to avoid/reduce the powerful signaling role of cNMP/
PDEs, key components of glucose transduction pathways 
[7]. For the same reason, KlADH3 has been preferred to 
commonly used promoters like LAC4, GAL7 and even 
KlADH4, genes partially induced in glucose-containing 
medium [18, 19, 27, 28].
These expression vectors were used for the quantita-
tive production of the Mus musculus PDE5 isoforms. We 
found that the expression of the M. musculus Pde5a1, 
a2 and a3 variants of the Pde5a gene, obtained from a 
pCDNA3.1-cloned cDNA embrio library [36], was well 
tolerated by K. lactis cells without major growth defi-
ciencies. PDE5A proteins, produced in large amounts, 
displayed biochemical properties identical to those of the 
native murine isoforms [37]. This process could poten-
tially be extended for the quantitative production of 
other higher eukaryotes PDE families.
Methods
Strains, media and culture conditions
The K. lactis CBS2359 (MATa) (http://www.cbs.knaw.nl) 
strain was used in this work. Cultures were grown under 
shaking conditions at 28 °C in YP (1% Difco yeast extract, 
2% Difco Bacto-peptone) or in minimal medium (6.7 g/L 
Difco Yeast Nitrogen Base) supplemented by carbon 
sources at the concentration specified in the text. Gene-
ticin (G418) concentration in selective conditions was 
100  μg/mL. Escherichia coli strain DH5α was used for 
the propagation of plasmid DNA. Cultures were grown at 
37 °C in LB medium (0.5% Difco yeast extract, 1% Difco 
tryptone, 0.5% NaCl, supplemented with 100  μg/mL 
ampicillin).
Construction of plasmids for the expression of the Pde5a1, 
a2 and a3 in K. lactis
Construction of pα‑PDE5A1
This vector contains the DNA coding for the killer toxin-
secretion peptide (α-signal) [34] fused in frame with the 
M. Musculus Pde5a1 cDNA gene. The α-signal DNA 
was synthesized as two short single strands complemen-
tary sequences containing at the 5′ and 3′ end the XbaI 
and SalI sites (Fwd: ctag atg aat ata ttt tac ata ttt ttg ttt 
ttg ctg tca ttc gtt caa ggt agg ggt gtg ttt cgt cga g; Rev: 
tc gac tcg acg aaa cac acc cct acc ttg aac gaa tga cag caa 
aaa caa aaa tat gta aaa tat att cat), respectively, and then 
annealed. The 2.6 Kbp SalI–SmaI PDE5A1 fragment was 
purified from p3XFLAG-CMV7 [36]. The two fragments 
were ligated into the Bluescript KS (Stratagene) plasmid 
digested with XbaI–SmaI. Transformation and screening 
of E. coli cells led to the isolation of pKS/αsignal-PDE5A1 
containing the α-signal DNA correctly fused at the 5′ 
end of the Pde5a1 gene. Finally, the recombinant gene, 
purified as a 2.7 Kbp XbaI-digested fragment from pKS/
αsignal-PDE5A1, was cloned in the NheI-digested site of 
pYG137/1 to harbour pα-PDE5A1 (Fig. 2b).
pYG137/1 (Fig. 2c) is a derivative of pYG132, a multi-
copy plasmid previously used for the production and 
secretion of the recombinant human serum albumin 
under the control of the KlADH4 gene promoter [33, 
35, 38]. This vector contains the entire pKD1 plasmid, 
the kanamycin bacterial gene that confers resistance to 
the G418 antibiotic in yeast, the promoter of KlADH3 
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[29–32] and the terminator of the S. cerevisiae PGK1 
gene.
pYG137/1 was also used to construct p3XFlagPDE5A1, 
p3XFlagPDE5A2 and p3XFlagPDE5A3 which contain 
the M. musculus Pde5a1, a2 and a3 spliced-variants of 
the Pde5 gene fused at their 5′ end to the short DNA 
sequence coding for the 3XFLAG peptide (Sigma), an 
immunogenic peptide for the affinity purification of PDEs 
from whole cellular extracts. These recombinant vectors 
were constructed in two stages from pα-PDE5A1 and the 
p3XFLAG-CMV7 vectors containing either Pde5a1, a2 
or a3 in frame with the 3XFLAG coding sequence [36]. 
To start, pα-PDE5A1 was digested with PmlI, ligated 
and transformed in E. coli cells. The screening of trans-
formants allowed the isolation of pYG137/1-PDE5Δ0.8, 
which contains a deletion of 0.8 Kbp of DNA coding for 
the α peptide and the first 0.75 Kbp of Pde5a1 (Fig. 2b). 
In the second stage, the p3XFLAG-CMV7 plasmids were 
digested with the enzymes EcoICRI and PmlI and the 
0.7–0.8 Kbp fragments (containing the 3XFLAG fused to 
the 5′ end of the three genes, respectively) were recovered 
from each digestion, purified and cloned in pYG137/1-
PDE5Δ0.8 digested with PmlI. The screening of E. coli 
transformed cells led to the isolation of p3XFlagPDE5A1, 
p3XFlagPDE5A2 and p3XFlagPDE5A3 (Fig. 2b).
We also constructed p-PDE5A1 (Fig.  2b) which con-
tains Pde5a1 under the control of the KlADH3 promoter. 
This vector was obtained by cloning the 0.8 Kbp PmlI–
EcoICRI fragment, containing the 5′ end of PDE5A1 
recovered from pcDNA3.1 [36], in the PmlI-digested 
pYG137/1-PDE5Δ0.8.
Preparation of cellular extracts and PDE activity assay
Kluyveromyces lactis cells harbouring the PDE5A plas-
mids (Fig.  2b) were grown under shaking conditions 
at 28  °C for up to 5  days in 5  mL of YP supplemented 
with glucose (YPD) or glycerol (YPG) at the concentra-
tion of 2%. Harvest cells were collected by centrifuga-
tion, washed twice with distilled water and resuspended 
in 300 μL of lysis buffer (20 mM Tris–HCl buffer pH 7.2, 
0.2 mM EGTA, 5 mM MgCl2, 5 mM β-mercaptoethanol, 
0.1% v/v Triton X-100, 2% v/v antiprotease cocktail 
(Sigma Aldrich, CA, USA), 1  mM PMSF) and broken 
with glass beads (∅ 0, 5  mm). The lysate was recovered 
by centrifugation at 14,000g for 30 min at 4 °C, ready for 
further analyses. The recovered pellets were resuspended 
in 200 μL of lysis buffer and analysed for PDE activity.
PDE activity was measured at 30  °C with the two-
step method described by [39] using  [3H]cGMP (Perkin 
Elmer, MA, USA). Aliquots of extracts were incubated 
in 60 mM HEPES pH 7.2 assay buffer containing 0.1 mM 
EGTA, 5 mM  MgCl2, 0.5 mg/mL bovine serum albumin, 
30 µg/mL soybean trypsin inhibitor, in a final volume of 
0.15 mL (PDE assay buffer). The reaction was started by 
adding tritiated substrate at a final concentration of 1 μM 
 [3H]cGMP and stopped by adding 0.1 M HCl. The Silde-
nafil used in enzymatic inhibition experiments was a gen-
erous gift from Pfizer.
Quantitative purification of the 3XFlagPDE5A1, A2 and A3 
isoforms
100  mL of YPG medium were inoculated with the 
CBS2359 strain, harbouring the 3XFlagPDE5A plasmids, 
and grown for 4 days under shaking conditions. All puri-
fication steps were carried out at 4  °C. Cells were har-
vested and broken in 10  mL of lysis buffer, as described 
above and the lysate centrifuged twice at 20,000g for an 
hour. The supernatant was collected, diluted 20 times in 
the purification buffer (50  mM HEPES pH 7.5, 75  mM 
NaCl, 37.5  mM  MgCl2) and loaded for three times in a 
chromatography column with an ANTI-FLAG M2 affin-
ity gel (Sigma-Aldrich) equilibrated with the purification 
buffer. The column was washed with 20  mL purification 
buffer. The elution of the 3XFlagPde5A proteins was per-
formed by competition with the 3XFLAG peptide (Sigma-
Aldrich) according to instructions. The eluted fractions 
were analyzed by western blotting and for PDE activity.
SDS‑PAGE and western blotting
The purity and integrity of proteins were assessed using 
SDS-PAGE. Protein samples were boiled for 3  min and 
subjected to 8% SDS-PAGE and then visualized by 0.1% 
Coomassie Brilliant Blue R-250 staining. For western 
blotting analysis, after the electrophoresis, the proteins 
were transferred to nitrocellulose membranes (Bio-Rad, 
Hercules, CA, USA). Blots were incubated overnight at 
4  °C with rabbit polyclonal anti-PDE5 antibody (1:1000; 
Santa Cruz Biotechnology). Alkaline phosphatase con-
jugated anti-rabbit IgG (1:5000; Sigma-Aldrich) was 
used as a secondary antibody to reveal the immune-
complexes. Immunoreactive bands were stained with 
nitroblue tetrazolium (0.3  mg/mL) in the presence of 
5-bromo-4-chloro-3-indolyl-phosphate (0.15 mg/mL).
In‑gel native ADH staining assay and PDE activity in gel 
slice
Cell extract preparation, native polyacrylamide gel elec-
trophoresis (PAGE), electrophoresis conditions and ADH 
staining assay were carried out as previously described 
[29]. PDE activities were recovered from the native gel 
slices with 100  μL of PDE assay buffer by over night-
incubation on ice. The samples were then centrifuged 
at 14,000g for 15 min at 4  °C and aliquots of the eluates 
assayed for cNMP hydrolysing activity.
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General methods
DNA manipulation, plasmid engineering and other 
techniques were performed according to standard pro-
cedures. Yeast transformation was performed by elec-
troporation with a Biorad Gene-Pulser apparatus. Protein 
concentration was determined according to the Bradford 
method [40].
Results
Analysis of the KlAdh3 activity by native PAGE ADH 
staining
KlADH3 is regulated at the transcriptional level by car-
bon sources and a native PAGE ADH staining assay can 
be used to show its expression [29–32]. To this end, wild 
type cells were grown for 2–3 days in YP medium con-
taining either fermentative, respiratory or switched to 
another substrate. Cellular extracts prepared from these 
cultures were fractioned on native PAGE and stained 
for ADH activity [29]. As shown in the ADH pattern 
reported in Fig.  1, KlAdh3 was absent when the cul-
tures were grown in 7% glucose or in ethanol (Fig.  1, 
lane 1 and 10) [29]. The pattern displayed KlAdh3 when 
extracts were prepared from cultures containing 2% glu-
cose or galactose (Fig. 1, lanes 3, 5 and 8). The amounts 
of KlAdh3 were only slightly increased when the cultures 
were switched from glucose to galactose (Fig. 1, lanes 2 
and 4 vs. 3) but these levels were highly increased when 
cells were switched from ethanol to other respiratory car-
bon sources like glycerol (lane 10 vs. 6). The extracts dis-
played the highest amounts of KlAdh3 when the cultures 
were grown for 2–3 days in YP medium containing either 
glycerol (Fig. 1, lanes 7 and 9), acetate (lane 11) or lactate 
(lane 12). In these conditions KlAdh3 was the only Adh 
present in the pattern (Fig. 1, lanes 7, 9 and 11–12). How-
ever, the growth in glycerol, acetate and lactate medium 
was not identical. In fact, the biomass yield obtained 
from glycerol, after 3–4 days of growth, was nearly twice 
the amounts produced in acetate and lactate medium 
(not shown).
Engineered plasmids for the production of the murine 
PDE5A1, A2 and A3 isoforms
The reported data suggested to us the use of the KlADH3 
promoter for the construction of an expression cassette. 
pYG137/1, a multicopy pKD1-derived vector [33], con-
tains this cassette with the KlADH3 promoter and the S. 
cerevisiae PGK1 terminator (Fig. 2c).
The aim of this work was to express Pde5a1 and 
secrete its product in the extracellular medium. There-
fore, the DNA sequence coding for the killer toxin 
α-peptide was fused in frame in front of the Pde5a1 
Fig. 1 Kluyveromyces lactis in-gel native ADH pattern. Cells were 
grown for 2–3 days in YP medium supplemented with the carbon 
sources at 2%, unless stated in the text. Extracts from these cultures 
fractioned on native PAGE were stained for ADH. The migrating 
positions of ADH isoforms are reported on the left. The  < >  symbols 
indicate switch of substrate after 2 days of growth
Fig. 2 Vectors used for the expression of Pde5a genes. a N-terminal 
variants of PDE5A1, A2 and A3 isoforms. b Plasmid PDE5A inserts. 
c Map of the pYG137/1 used for the expression of PDE5A1 and 
recombinant derivatives. pKD1 sequences in grey. α-peptide/3XFlag 
schemes are not in scale with those of PDE5A
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gene. This peptide, engineered for production of human 
serum albumin, has proved to be an efficient targeting 
export signal for many heterologous proteins [24, 34, 35, 
41]. The final construct, containing the chimeric gene in 
pYG137/1, was called pα-PDE5A1 (Fig.  2b). pYG137/1 
was also used to express the native murine Pde5a1 and 
Pde5a1, a2 and a3 alternative spliced mRNA variants 
of the Pde5 gene only differing in their N-terminal cod-
ing products (Fig.  2a) [36] in frame with the 3XFLAG 
DNA. This sequence encodes an immunogenic peptide 
used for the affinity purification of the PDE5A isoforms 
(Fig. 2b). The latter plasmids, called pPDE5A1, p3XFlag-
PDE5A1, p3XFlagPDE5A2 and p3XFlagPDE5A3, were 
constructed for the intracellular quantitative produc-
tion of the native and recombinant PDE5A isoforms 
(see below).
Use of the KlADH3 promoter for the production of PDE5A1
pα-PDE5A1 was introduced by electroporation in the K. 
lactis CBS2359 strain and transformants were grown for 
up to 5 days in YP medium containing glycerol, a carbon 
source that induces KlADH3 [29].
To prove that the KlADH3 promoter is suited for the 
production of PDE5A1, cellular extracts, prepared from 
wild type and transformed strain cultures grown in glyc-
erol and glucose medium, were fractioned on native 
PAGE and stained for ADH activity. As shown in Fig. 3a, 
both strains displayed increased amounts of KlAdh3 
activity in glycerol conditions (lanes 4–6 and 10–12) as 
compared with glucose-grown cultures (lanes 1–3 and 
7–9). Moreover, cellular extracts prepared from YPG-
grown cultures displayed higher amounts of cGMP 
hydrolysing activities at increased days of growth only 
in the transformed strain (Fig. 3b) and with a profile that 
reflects that of KlAdh3 (Fig.  3a, lanes 10–12). In con-
trast, the wild type only showed very low levels of cGMP-
hydrolysing activity independently of the days of growth 
(Fig. 3b).
The glycerol- and glucose-extracts from the trans-
formed strain (Fig. 3a, lanes 7–12) were also analysed by 
immuno blot to determine the intracellular accumulation 
levels of the α-PDE5A1 protein (Fig. 3c). The PDE5 anti-
body revealed the presence of at least two bands, a faint 
one of 100 kDa mainly visible at 2 days of growth (Fig. 3c, 
lane 2 and 5) and a slower migrating band of about 
130  kDa accumulated at higher levels in extracts from 
respiratory carbon source grown-cultures (lanes 1 and 
6–8). In contrast, cells grown in YPD showed very low 
levels of activity (Fig.  3c, lanes 2–4). The lactate-grown 
culture accumulated higher amounts of putative PDE5A1 
than glycerol and acetate-grown ones (Fig. 3c, lane 8 vs. 
lanes 1 and 7) but, as stated earlier, with a lower biomass 
yield.
The α‑signal is incapable of promoting the secretion 
of PDE5A1
To prove that the slower migrating bands visualized in the 
immuno blot (Fig.  3c, lanes 1 and 6–8) and the cGMP-
hydrolysing activities, accumulated by the pα-PDE5A1 
transformed strain (Fig.  3b, days 1–5), are PDE5A1, we 
assayed both soluble and pellet fractions of the extracts in 
the presence of Sildenafil, the specific inhibitor of PDE5. 
Indeed, as reported in Fig.  3d, whole extracts showed 
highly reduced levels of activity in the presence of Silde-
nafil in both soluble and pellet fractions confirming its 
identity. However, the amounts of PDE5 measured in the 
pellet fraction were ten times higher than in the soluble 
fraction. In contrast, a very small amount of activity was 
measured in the pellet fraction of the parental untrans-
formed strain and at even lower levels than in the soluble 
fraction (Fig. 3d).
Unexpectedly, a very small amount of PDE (0.85 pmol 
cGMP hydrolised/min/mL) was measured in the medium 
supernatant of the transformed glycerol-grown strain but 
only after it was concentrated 20 times (Fig. 3e).
To test whether the α-signal is suited for the secretion 
of PDE5A1 in the medium, the cellular extracts and the 
medium fractions were concentrated and subjected to 
immuno blot analysis. The PDE antibody showed the 
presence of three putative bands of PDE5A1 in the cellu-
lar extract (Fig. 3e, lanes 2) indicating that large amounts 
of the chimeric protein are blocked inside the cell and 
unable to be secreted in the medium supernatant. In 
fact, only one of these bands corresponds to the faint one 
detected in the concentrated growth medium and to the 
PDE5A1 control band fractioned from the N18TG2 cells 
extract (Fig. 3e, lanes 4 and 5). N18TG2 is a murine neu-
roblastoma cell line with very high levels of PDE5A1 [42, 
43].
To determine the migrating properties of the endog-
enous K. lactis PDE activities with those of the heter-
ologous PDE5A1, we performed a native PAGE analysis 
of the cellular extracts from the transformed and wild 
type strain cultures. Although a native staining method 
to reveal the PDE activities exists [44], we were unable 
to visualize bands of PDE with this method (not shown). 
To overcome this problem, we cut the loaded gel lanes in 
20 consecutive slices (three mm large), elute the proteins 
and test each sample for cAMP and cGMP hydrolysing 
activities. Slices from wild type extract showed coinci-
dental cNMP hydrolysing activities mainly concentrated 
in the fractions 10–12 (Fig. 4, upper panel). Although the 
role of cGMP as second messenger in the metabolism of 
lower eukaryotes has not been characterized, K. lactis like 
S. cerevisiae [9] harbours PDE activities able to hydrolyse 
both cNMP. The transformed strain expressed, beside the 
endogenous PDEs (Fig.  4 lower panel, fractions 10–12), 
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other additional and specific slower migrating peaks of 
cGMP-hydrolysing activities (fractions 5–7). Moreover, 
this strain displayed, another huge peak of PDE in the 
first slice of the gel, activities probably associated with an 
aggregate of proteins unable to enter and migrate in the 
gel field. The great amount of activity present in this sam-
ple (Fig.  4 lower panel, fraction 1) confirmed that most 
of the PDE activities remained probably entrapped in the 
membranes.
Kluyveromyces lactis produces high levels of native PDE5A1 
and recombinant 3XFlagPDE5A1 activities
The cells’ inability to secrete PDE5A1 into the medium 
led us to quantify the intracellular PDE5 accumulated 
by the p-PDE5A1 and p3XFlagPDE5A1 transformed 
strains (Fig.  2b). The cellular extract from the glycerol-
grown p-PDE5A1 harbouring strain, once fractioned in 
SDS-PAGE and stained with Coomassie, showed a large 
band of the expected molecular weight (MW) of PDE5A1 
(Fig.  5a, lane 2), a band absent in the control untrans-
formed strain (lane 1). This band was confirmed to be the 
murine protein by immunoblot analysis (Fig. 5a, lane 4) 
and its activity was determined in the intracellular solu-
ble fraction (Fig. 5b). Indeed, differently from the strain 
harbouring pα-PDE5A1 (Fig.  3d), the amounts of PDE 
determined in the pellet of the p-PDE5A1 strain were 
Fig. 3 Analysis of ADH and PDE5 activities from cellular extracts.  
a In-gel native ADH pattern from the wild type (WT) and pα-PDE5A1 
transformed strain. Cells were grown in YPG or YPD medium for 
1–5 days. The migrating position of ADH isoforms is reported on 
the left. b cGMP hydrolysing activities from extracts of WT and 
pα-PDE5A1 transformed strain. Extracts were obtained from YPG-
grown cultures of a. c Western blot of PDE5A1 from the 2–4 days 
YPD- YPG-grown cultures extracts of a (lanes 7–12) and extracts from 
YP lactate or acetate cultures. d cGMP hydrolysing activities with/
without 200 nM Sildenafil (sild). Soluble (s) and pellet fraction (p) 
were from the 4 days YPG-grown cultures extracts of a. e Western 
blot of PDE5A1 from the 4 days YPG-grown cellular extracts and 
medium supernatants of a concentrated 20 times. N18TG2 (N18) 
murine neuroblastoma cell line extract is used as PDE5 standard. 
Each lane contains 10 μg of protein extract for ADH analysis, 30 μg 
for western blot of PDE or the concentrated equivalent of 0.3 mL of 
medium supernatant. Arrows indicate the migrating position of PDE5 
bands
◂
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only a portion of the amounts found in the soluble frac-
tion (Fig. 5b).
Finally, we compared the amounts of PDE5A1 pro-
duced in the strains transformed with either pα-PDE5A1, 
p-PDE5A1 or with p3XFlagPDE5A1. As shown by the 
arrow in the Coomassie-stained SDS-PAGE (Fig.  5c, 
lanes 1–3) and by the histograms (Fig. 5d), the activities 
determined in the intracellular soluble fractions of the 
three strains suggested that p-PDE5A1 and p3XFlagP-
DE5A1 are good vectors for the quantitative production 
of the PDE5A1 isoform. In contrast, the pα-PDE5A1 
strain was confirmed to be unable to accumulate signifi-
cant amounts of intracellular PDE5A1 (Fig. 5d).
Growth curves and viability of pα‑PDE5A1 
and p3XFlagPDE5A1 transformed strains
The production of heterologous proteins is a stress con-
dition that triggers a large common adaptive response, 
which in yeast is called environmental stress response 
[24, 45]. Therefore, the 3XFlagPde5A1-producing culture 
Fig. 4 Native PAGE-migrating properties of cAMP/cGMP hydrolysing activities from WT and pα-PDE5A1 culture extracts. The activities of both 
extracts were determined in CPM (counts per minute) in the sequentially-sliced (1–20) migrated extracts shown in the Coomassie-stained gel insert. 
Extracts were obtained from cells grown in YPG medium for 4 days
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was compared with the one producing α-PDE5A1 that 
accumulating in the larger part in the insoluble pel-
let fraction could be subjected to stress. Cell growth at 
time intervals and cell viability at the end of the 4 days of 
growth were measured. As shown in Fig. 6a, both trans-
formed strains displayed reduced growths in lag-expo-
nential phases that were recovered to nearly wild type 
level in the p3XFlagPDE5A1 strain at 4 days of growth. In 
contrast, the strain transformed with pα-PDE5A1 grew 
at half the level of the parental strain and reached a pre-
cocious stationary phase after 36  h of growth (Fig.  6a). 
This data confirmed that the secretion signal in front of 
PDE5A1 had a negative effect on the growth of the trans-
formed cells. Indeed, as shown in Fig. 6b, the viability of 
the cells, determined as the % of cells capable of form-
ing colonies on plate (cfu) showed in the pα-PDE5A1-
containing culture a viability reduced to 50% of that of 
the other two strains.
The strains transformed with 3XFlagPde5A2 and 
3XFlagPde5A3 showed growth curves and viabilities 
almost identical to that of the p3XFlagPDE5A1 strain 
(not shown). These results confirmed that overexpression 
of the murine genes in K. lactis leads to a slower adapta-
tion of the cultures, as compared to the parental untrans-
formed strain (Fig. 6a).
Finally, extracts prepared from the p3XFlagPDE5A1-
transformed strain, grown for 2–4  days in rich glucose 
Fig. 5 Analyses of PDE5 activities from cellular extracts. a SDS-PAGE 
analysis by Coomassie-staining and western blot of extracts from the 
WT and the pPDE5A1 transformed strain. b cGMP hydrolysing activi-
ties from the soluble (s) and pellet fraction (p) extracts of a. c SDS-
PAGE analysis by Coomassie-staining of extracts from the pα-PDE5A1, 
the pPDE5A1 and the p3XFlagPDE5A1 transformed strains. d 
Determination of cGMP hydrolysing activities from the extracts of c. 
Cultures were grown in YPG medium for 4 days. Each lane contains 
10 μg of protein extract. The arrows indicate the bands of PDE5A1
Fig. 6 Growth curves and viability of PDE5-transformed strains.  
a Growth curve of WT, pα-PDE5A1 and p3XFlagPDE5A1 transformed 
strains. Cultures were grown in YPG medium for 4 days and  OD600 
determined at time intervals. Each value is the average of three 
independent determinations with a standard deviation comprised 
between 4 and 13%. b Cell viability of cultures of A was determined 
at the end of 4 days of growth. Cell cultures were diluted to  108 cell/
mL and the viability expressed as % of those forming colonies on YPD 
plates. c Western blot of PDE5A1 from the 2–4 days YPD-YPG-grown 
cultures extracts of the p3XFlagPDE5A1 strain. Each lane contains 
4 μg of proteins. S. cerevisiae Pgk1 antibody was used as loading 
standard
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or glycerol medium, were compared for the production 
of the 3XFlagPDE5A1 isoform by immuno blot using a 
PDE5 antibody. As shown in Fig.  6c, a small amount of 
3XFlagPDE5A1 was visible in the extracts from glucose-
grown cells and these levels were independent from the 
days of growth (lanes 2–4). On the contrary, high levels 
of 3XFlagPDE5A1 were produced in glycerol-containing 
medium and greatly increased at 3 and 4 days of growth 
(Fig.  6c, lanes 5–7). The amounts of 3XFlagPDE5A1 
accumulated in the two conditions coincide with the 
levels of KlAdh3 produced in the same conditions in the 
parental and transformed strains (Fig. 3a).
Production and purification of the 3XFlagPDE5 isoforms
The strain harbouring the p3XFlagPDE5A1 construct 
was used for the quantitative production of the protein. 
To this end 100 mL of culture was grown under shaking 
conditions for 4  days, harvested cells were then lysated 
and the soluble fraction recovered by centrifugation. 
The 3XFlagPDE5A1 protein was purified from the total 
extract using an ANTI-FLAG M2 affinity chromatogra-
phy column and eluted by competition with the 3XFLAG 
peptide. The purification steps with the whole extract, 
the flow-through, the eluted fractions and the known 
amounts of BSA, used to quantify the 3XFlagPDE5A1 
protein, are shown in the Coomassie-stained SDS-PAGE 
of Fig.  7 (lanes 1–8). Identical results were obtained 
for the quantitative production of the 3XFlagPDE5A2 
(Fig. 7, lanes 9–16) and the 3XFlagPDE5A3 (not shown). 
The MW of the three purified isoforms is shown in the 
Coomassie-stained SDS-PAGE of Fig.  7 (lanes 17–19). 
The amounts of the three purified isoforms, obtained 
from the eluted fractions of 100 mL of YPG culture, were 
estimated to be between 2.75 and 2.96 mg corresponding 
to a yield of nearly 30 μg of protein for mL of culture.
The purified 3XFlagPDE5A1 was analyzed for kinetic 
and inhibition properties. In Fig.  8a is reported the 
Eadie–Hofstee graphical representation of PDE5A1 
kinetic with a calculated Km of 1.08 ± 0.08 μM and  Vmax 
of 1.82  ±  0.04  μmol/min/mg, values not significantly 
different from those measured in human activity [37]. 
The inhibitory effect of Sildenafil on PDE5A1 activ-
ity, determined using the nonlinear regression analysis 
of the sigmoidal dose response (Fig.  8b), gave an  IC50 
of 4.7  ±  1.1  nM, a value very similar to that obtained 
from mouse neuroblastoma immunoprecipitates [46] 
and human recombinant isoform [47]. Moreover, pre-
incubation of the 3XFlagPDE5A1 protein with Sildenafil 
displayed in native Coomassie-stained PAGE an electro-
phoretic mobility shift determined by the bond of the 
inhibitor with the catalytic site of the protein (Fig.  8c) 
[48]. Biochemical analysis and inhibition potency of 
Sildenafil determined on PDE5A2 and A3 purified iso-
forms gave identical results (not shown).
Discussion
PDEs are cyclic nucleotides hydrolysing enzymes 
grouped into two classes of proteins with distinct/dual 
substrate hydrolysing specificity for cAMP and cGMP. 
Class I groups together more than hundred higher eukar-
yote isoforms into eleven PDE families (PDE1 to PDE11) 
[4]. PDE5, one of these families, has three isoforms (A1, 
A2 and A3) (Fig. 2a) encoded by the a1, a2 and a3 alter-
native-spliced variants of the Pde5a gene. PDE5 has a 
major role as cGMP-dependent regulator of vascular 
smooth muscle contractions and it has been identified 
as the target of several well-known drugs [5]. The large 
profit generated by the commercialisation of these drugs 
led their exploitation for other pathologies expanding the 
study of PDE5 to other organs. Recently, PDE5 has been 
shown to be involved in learning/memory processes, in 
heart failure, in cardio-vascular diseases and in human 
breast and thyroid cancers [49–53]. Despite the great 
commercial relevance of these drugs, productions of 
large amounts of PDE5 isoforms for the development of 
new specific inhibitors or for the crystal structure deter-
mination of the entire PDE5 proteins have either not 
been carried out or if so, not published. At the moment, 
crystallographic models have only been constructed for 
the single catalytic/regulatory domains [54].
Fig. 7 Coomassie-stained SDS-PAGE analysis of the 3XFlagPDE5 isoforms purification processes. The figure reports the whole protein extracts (WE), 
the flow-through (FT) and the eluted fractions (I, II and III) of the A1 (lanes 1–8) and A2 (lanes 9–16) isoforms purified by an ANTI-FLAG M2 affinity 
chromatography column. The figure also reports the different MW of the three purified isoforms (lanes 17–19). WE was from 100 mL of YPG cultures 
grown for 4 days. BSA standards were used for the quantification
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In this paper, we showed that the α-peptide signal, 
in contrast with previous proteins-secretion reports, 
is unable to target PDE5A1 in the extracellular space 
(Fig.  3e). In fact, native PAGE, immuno blot analysis 
and PDE determinations from the protein extracts of 
the pα-PDE5A1 strain showed that a large amount of 
the enzyme was located in the insoluble pellet fraction 
(Figs.  3d, 4 fraction 1) and only a very small amount of 
PDE5 was detected in the medium (Fig. 3e, lane 4). More-
over, the intracellular accumulated activity displayed 
PDE5 bands with MWs that vary according to dilutions 
and/or concentrations of the protein extract (Fig.  3c, e, 
lane 2). In addition, the pα-PDE5A1 strain enters into 
a stationary phase at only 36  h of growth showing a 
reduced vitality, as compared to the other strains (Fig. 6a, 
b). Since PDEs are components of intracellular signaling 
pathways, we speculate that the bands of Fig.  3c–e and 
the activity of the pellet fraction accumulate as unpro-
cessed α-PDE5A1 suggesting the presence of domains 
conflicting with the secretory apparatus.
On the contrary, the expression cassettes lacking the 
α-signal allowed the intracellular accumulation of large 
amounts of the PDE5A1, A2 and A3 isoforms (Figs. 6c, 7). 
PDE5 yields, nearly 1 mg/g wet weight biomass (30 mg/L 
culture), are well tolerated by K. lactis cells without major 
growth deficiencies and interferences with the endog-
enous cAMP/cGMP signal transduction pathways.
These results were made possible by the choice of 
the host organism, by the use of the KlADH3 promoter 
expression vectors and by the growth conditions. K. lac-
tis is a Crabtree-negative yeast in which both respira-
tory and fermentative metabolisms coexist during its 
growth on glucose. Respiratory growth could be an ideal 
neutral condition to produce PDE5 isoforms avoiding 
interferences with glucose transduction pathways [6, 
7]. Conversely, KlADH3 is a gene highly induced dur-
ing the growth under respiratory growth conditions and 
pYG137/1 is a multicopy natural pKD1-derived vector. 
Finally, K. lactis transformed strains grow to high yields 
in rich glycerol medium with only a slightly delayed 
growth up to early stationary phase (Fig.  6a). A delay 
probably due to the gradual adaptation of the cells to the 
synthesis of PDE5A1 accumulating at constant rates dur-
ing growth phases (Figs. 3b, 6c).
In prospective, the large amounts of the three puri-
fied proteins produced could help to define their mac-
romolecular structure by small-angle X-ray scattering 
(Saxs)/crystallographic studies, to compare the differ-
ences between the three isoforms with known structures 
of other mammalian PDEs [54–56] and for the devel-
opment of new inhibitors for clinical and therapeutic 
applications.
Conclusions
In this paper we report the KlADH3 promoter-dependent 
production of the M. musculus PDE5A isoforms in K. lac-
tis. The use of this promoter was the appropriate choice 
for the production of PDE5 isoforms as it proved to be 
well tolerated by K. lactis cells. To our knowledge this 
is the first time that the entire family of PDE5 isoforms 
Fig. 8 Biochemical properties of the purified 3XFlagPDE5A1 protein. 
a Eadie-Hofstee representation plot of cGMP hydrolysis. b Sildenafil 
inhibition curve. c Native PAGE gel shift by pre-incubation of 3XFlag-
PDE5A1 with Sildenafil. The purified 3XFlagPDE5A1 protein (1 μg) was 
incubated for 15′ at 30 °C with the inhibitor, fractioned on gel and 
stained with Coomassie
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containing both regulatory and catalytic domains has 
been produced in a heterologous eukaryotic organism. 
The three purified proteins will be used to define their 
macromolecular structure by crystallographic studies 
and to compare putative differences between the three 
isoforms and other mammalian PDEs. These results 
established K. lactis as a model organism for production 
of mammalian PDE and, in prospective, as a platform to 
increase their yields by the control of the growth parame-
ters, the use of alternative carbon sources/media and the 
genetic manipulation of the host.
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